Company intelligence / Profile preview
Northfield Laboratories
- Ownership
- Private
- Development stage
- Other
Overview
Northfield Laboratories developed PolyHeme, a human polymerized hemoglobin-based oxygen therapeutic (blood substitute), which failed to secure FDA regulatory approval due to safety concerns—specifically, increased mortality at 30 days. The company ceased all operations and liquidated following the FDA's rejection.
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- ProteinBiologic
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Northfield Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Northfield Laboratories.